Onvansertib (Not yet branded)
Other Medications
Description
Onvansertib is a small molecule polo-like kinase 1 (PLK1) inhibitor being developed for treatment of metastatic colorectal cancer, particularly in patients with KRAS mutations. The drug is administered in combination with standard chemotherapy regimens including FOLFIRI and bevacizumab or FOLFOX and bevacizumab for second-line treatment. Clinical trials have focused on its potential efficacy in RAS-mutated colorectal cancers, where limited targeted therapy options exist.
Mechanism of Action
Onvansertib selectively inhibits polo-like kinase 1 (PLK1), a serine/threonine kinase essential for cell cycle progression, particularly during mitosis. By blocking PLK1 activity, the drug disrupts spindle formation and chromosome segregation, leading to mitotic arrest and apoptosis in rapidly dividing cancer cells.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Other Medications |
 Status | Experimental |
 EMA Status | Experimental |
 Spain Access | Not available |
| Administration | Oral |
| Clinical Trials | 3 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.